of new targeting strategies aimed at complete disease elimination, allowing for discontinuation of life-long TKI therapy. miR-126-3p (hereafter referred to as miR-126) is highly expressed in normal HSCs and hematopoietic progenitor cells (HPCs) and restrains cell-cycle progression during hematopoiesis 4 . We and others have shown that increased miR-126 levels are associated with an increased frequency of quiescent LSCs and a worse outcome in individuals with acute myeloid leukemia (AML) [5] [6] [7] [8] . Here we show that miR-126 biogenesis in CML LSCs is downregulated through a BCR-ABL-dependent mechanism, a finding that is seemingly inconsistent with a pro-leukemic role for miR-126. However, miR-126 is also highly expressed in ECs 9 . Anatomical and functional connections between the endothelium and normal HSCs regulate normal hematopoiesis 10 . We hypothesized that miR-126 may mediate a functional interplay between ECs and LSCs in the leukemia BM niche that regulates CML progression. Consistent with this hypothesis, we found that ECs supply miR-126 to CML LSCs to modulate their quiescence and self-renewal.
RESULTS
Higher miR-126 levels are associated with human and mouse CML LSCs miR-126 has been shown to contribute to leukemogenesis in individuals with acute leukemia 6, 8, 11 . To evaluate miR-126 expression in subpopulations of cells from individuals with CML, we sorted immunophenotypically defined subsets of HPCs (Lin − CD34 + (CD34 + ) and Lin − CD34 + CD38 + (CD38 + )), HSCs (Lin − CD34 + CD38 − (CD38 − ) and Lin − CD34 + CD38 − CD90 − (CD90 − )) and LT-HSCs (Lin − CD34 + CD38 − CD90 + (CD90 + )) from peripheral blood (PB) and BM samples of healthy donors (n = 12) and newly diagnosed patients with chronic-phase (CP) CML (n = 12). LT-HSCs from both healthy donors and individuals with CML showed the highest expression of miR-126 ( Fig. 1a,b) . Similar results were obtained in wild-type (WT) B6 and inducible SCLtTA×BCR-ABL transgenic B6 mice, a well-established mouse model of CML 12 (hereafter referred to as CML mice). We isolated Lin − Sca-1 − c-Kit − (L − S − K − ), Lin − Sca-1 − c-Kit + (L − S − K + ) (which includes common myeloid progenitor (CMP), granulocyte-macrophage progenitor (GMP) and megakaryocyte-erythrocyte progenitor (MEP) cells), Lin − Sca-1 + c-Kit + (LSK) and LSK Flt3 − CD150 + CD48 − (LT-HSC) cells from the BM of WT mice and CML mice after induction of BCR-ABL expression by tetracycline withdrawal (Supplementary Fig. 1a ). As in the human samples, LT-HSCs from healthy and CML mice showed the highest expression of miR-126 ( Fig. 1c,d) .
To test the effects of miR-126 on the quiescence of LSCs from subjects with CML, we knocked down MIR126 or Mir126a expression in human CML Lin − CD34 + CD38 − cells (HSCs) and mouse CML LT-HSCs, respectively, using GFP-expressing miRZip lentiviral vectors that also encode a MIR126-specific (for human HSCs) or Mir126a-specific (for mouse LT-HSCs) short hairpin RNA (shMIR126 or shMir126a, respectively; hereafter collectively referred to as miR-126 KD) or a miR-126-encoding precursor (for overexpression; hereafter referred to as miR-126 OE). After transduction, GFP + cells were selected and cultured for 72 h. miR-126 KD increased cell cycling and apoptosis, decreased the number of colony-forming cells (CFCs) and decreased the CFC-replating efficiency of both human CML HSCs ( Fig. 1e-i) and mouse CML LT-HSCs ( Fig. 1j-m) ; conversely, miR-126 OE decreased cell cycling and apoptosis and increased CFC-replating efficiency. We validated these results in vivo, first by showing that the quiescent Hoechst − Pyronin − (G0) fraction of CML LT-HSCs from induced SCLtTA×BCR-ABL mice (CD45.2) expressed significantly (P = 0.0019) higher miR-126 levels than the proliferating Hoechst − Pyronin + and Hoechst + Pyronin + (G1-, G2-, S-and M-phase) fractions of CML LT-HSCs (Fig. 1n) . The association of miR-126 with LSC activity was then demonstrated by showing that quiescent CML LT-HSCs had a significantly higher rate of long-term engraftment and leukemogenic capacity than did proliferating CML LT-HSCs after transplantation into CD45.1 congenic recipient mice (Fig. 1o,p) .
BCR-ABL downregulates miR-126 expression in CML cells
Although miR-126 has similar patterns of expression and function in CML as in normal hematopoiesis 4 , we noted that human CML Lin − CD34 + CD38 − (HSCs) and Lin − CD34 + CD38 − CD90 + (LT-HSCs) cells had significantly lower miR-126 levels than their normal counterparts ( Fig. 2a,b) ; similar differences were also observed in mouse samples (Fig. 2c) . Consistent with this finding, CML HSCs and LT-HSCs expressed higher levels of phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2) and SPRED1, two validated targets of miR-126 (refs. 4,7,9,13,14) , as compared to their normal counterparts ( Supplementary Fig. 1b,c) .
This differential expression of miR-126 observed led us to postulate that BCR-ABL itself might be involved in lowering miR-126 levels in CML cells. To test this hypothesis, we transduced LSK cells from the BM of healthy mice with retroviral BCR-ABL1-expressing or control vectors, selected GFP + cells and cultured them for 72 h. We found that induction of BCR-ABL expression ( Fig. 2d) resulted in decreased miR-126 expression ( Fig. 2e) and increased PIK3R2 and SPRED1 expression, as compared to the control cells ( Supplementary  Fig. 1d,e ). This was associated with an increase in cell cycling ( Fig. 2f ) and cell growth ( Fig. 2g) . To further validate this finding, we sorted LT-HSCs from non-induced BCR-ABL-transgenic mice and cultured them with or without tetracycline to repress or induce BCR-ABL expression, respectively. After tetracycline withdrawal and induction of BCR-ABL expression ( Fig. 2h) , we observed reduced miR-126 levels (Fig. 2i) as well as increased cell cycling ( Fig. 2j ) and cell growth ( Fig. 2k) , as compared to non-induced controls. Conversely, inhibition of BCR-ABL activity by treatment with nilotinib (NIL), a first-line TKI for CML treatment, led to increased miR-126 expression ( Fig. 2l-n) , decreased PIK3R2 and SPRED1 levels ( Supplementary  Fig. 1f,g) and an increased fraction of quiescent cells in human CML HSCs ( Fig. 2o) but not in normal HSCs (Supplementary Fig. 1h) , as compared to cells treated with vehicle alone. NIL treatment also resulted in increased miR-126 expression in human BCR-ABL + K562 cells (Supplementary Fig. 1i ).
BCR-ABL deregulates miR-126 biogenesis
Whereas CML cells harbored lower levels of mature miR-126 than their normal counterparts, we noted that BCR-ABL + cells had higher levels of primary (pri-) and precursor (pre-) miR-126 than their normal counterparts (Fig. 3a,b) . This result led us to hypothesize that BCR-ABL might interfere with miR-126 biogenesis.
Nucleus-to-cytoplasm shuttling and maturation of miRNAs are mediated by a protein complex comprising the GTP-binding RASrelated nuclear protein RAN, exportin-5 (XPO5; also known as EXP5) and regulator of chromosome condensation 1 (RCC1) 15 . After activation via tyrosine phosphorylation, SPRED1 functions as a negative regulator of RAS superfamily proteins 16 . We therefore postulated that the BCR-ABL tyrosine kinase can phosphorylate SPRED1, allowing SPRED1 to bind RAN, and that this binding interferes with RAN-, EXP5-and RCC1-mediated shuttling and maturation of miR-126. © 2018 Nature America, Inc., part of Springer Nature. All rights reserved.
Using immunofluorescence (IF), immunoprecipitation (IP) and in vitro kinase activity assays to analyze BCR-ABL + primary CD34 + cells and/or K562 cells, we showed that SPRED1 colocalized with BCR-ABL to the cytoplasm (Fig. 3c) , was directly phosphorylated by BCR-ABL (Fig. 3d) , and formed an intranuclear or perinuclear protein complex with RAN ( Fig. 3e,f) . NIL treatment reversed these effects, resulting in SPRED1 dephosphorylation ( Fig. 3d, left) , decreased binding and colocalization of SPRED1 with RAN ( Fig. 3f) , increased formation of the RAN-EXP5-RCC1 complex (Fig. 3g,h) , decreased pri-and pre-miR-126 levels, and increased mature miR-126 levels (Fig. 3i) . In cells that were washed to remove NIL, the binding of SPRED1 with RAN was restored, the binding of RAN with EXP5-RCC1 was decreased ( Fig. 3j) , pri-miR-126 levels were increased ( Fig. 3k) and mature miR-126 levels were reduced ( Fig. 3k,l) . Northern blot analysis confirmed that the ratio of pri-and pre-miR-126 levels to mature miR-126 levels decreased after exposure of BCR-ABL + cells to NIL and increased after washing off NIL ( Fig. 3m) . SPRED1 knockdown (KD) by short interfering RNA (siRNA) in BCR-ABL + primary CD34 + and K562 cells enhanced formation of the RAN-EXP5-RCC1 complex ( Fig. 3n ) and resulted in decreased pri-and pre-miR-126 levels ( Fig. 3o ) and increased mature miR-126 levels (Fig. 3o,p) . Conversely, RAN KD by siRNA resulted in increased pri-and pre-miR-126 levels and reduced mature miR-126 levels ( Fig. 3q-s) . These results indicated that, in CML cells, BCR-ABL-induced SPRED1 phosphorylation interfered with RAN-EXP5-RCC1-mediated miR-126 biogenesis and lowered mature miR-126 levels. Given that miR-126 suppresses SPRED1 expression, this BCR-ABL-mediated reduction in miR-126 biogenesis may cause a further increase in SPRED1 levels, such that higher SPRED1 levels result in lower mature miR-126 levels (Supplementary Fig. 1j ) and that the endogenous levels of miR-126 are therefore controlled by its own target (SPRED1) in BCR-ABL + cells.
Of note, BCR-ABL-dependent deregulation of miRNAs is unlikely to be restricted to downregulation of miR-126. In Throughout, results shown represent mean ± s.e.m. *P ≤ 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n.s., not significant; by two-tailed, paired Student's t-test.
LSK cells from BCR-ABL-induced and non-induced CML mice, we found that levels of a total of 33 miRNAs (including miR-126-3p and miR-126-5p, miR-125a-5p, miR-125b-5p, miR-181a-3p, miR-181b-5p and miR-29b-3p) were substantially decreased and levels of 75 miRNAs (including miR-142-3p and miR-142-5p, miR-146b-3p, miR-146b-5p and miR-486-5p) were markedly increased (GSE107431; Supplementary Fig. 1k ), suggesting that distinct BCR-ABL-dependent mechanisms cause miRNA deregulation in CML.
Endothelial cells in the BM niche supply miR-126 to CML LSCs
Given that miR-126 is necessary for the quiescence of LSCs and that BCR-ABL activation causes downregulation of mature miR-126 levels in LSCs, we reasoned that an exogenous source of miR-126 might be needed for BCR-ABL + LSCs to maintain quiescence and prevent clonal exhaustion. BCR-ABL + LT-HSCs mainly reside in the BM niche, along with multiple regulatory nonhematopoietic cell types.
miR-126 is one of the most abundantly expressed miRNAs in ECs and is involved in angiogenesis 17, 18 . Consistent with this, we found that, in both normal and CML mice, BM ECs (CD45 − Ter119 − CD31 + ) expressed the highest levels of miR-126 as compared to LT-HSCs and other BM stromal cell populations, including osteoblasts (OBs; CD45 − Ter119 − CD31 − CD166 + Sca-1 − ) 19 and mesenchymal stem cells (MSCs; CD45 − Ter119 − CD31 − CD166 − Sca-1 + ) 20 (Fig. 4a,b) . We therefore hypothesized that ECs supply miR-126 to CML LT-HSCs.
To test this hypothesis, we sorted ECs from the endosteal and central marrow of SCLtTA×BCR-ABL mice and transduced these cells with lentiviral vectors expressing GFP and either shMir126a or a control shRNA (shControl) ( Fig. 4c) . LT-HSCs from induced SCLtTA×BCR-ABL mice were then cocultured with GFP + shControl-or shMir126a-expressing ECs or were cultured without ECs for 96 h and analyzed for cell cycle and cell growth. After collecting the LT-HSCs that were in suspension, we separately collected the (m) miR-126 expression, as assessed by qPCR, in human CML Lin − CD34 + CD38 − cells that were treated with DMSO (Ctrl), or 2 µM or 5 µM NIL (n = 5 independent samples). (n) miR-126 expression, as assessed by staining for miRNA, in normal and CML Lin − CD34 + CD38 − cells that were treated with DMSO or NIL (5 µM). The experiments were repeated using four independent samples with similar results. Scale bar, 5 µm. (o) Cell cycle analysis of human CML Lin − CD34 + CD38 − cells that were treated with DMSO (Ctrl) or 5 µM NIL (n = 4 independent samples). Throughout, results shown represent mean ± s.e.m. *P ≤ 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n.s., not significant; by two-tailed, unpaired Student's t-test.
EC-attached LT-HSCs by flushing them gently from the culture flask with PBS buffer. EC-attached LT-HSCs were stained with CD45 to exclude EC contamination. CML cells that were cocultured with shControl-expressing ECs showed higher miR-126 levels ( Fig. 4c) , decreased cell cycling ( Fig. 4d) , decreased apoptosis ( Fig. 4e) , decreased cell growth ( Fig. 4f) and an increased frequency of LT-HSCs (Flt3 − CD150 + CD48 − LSK) ( Fig. 4g) , as compared to CML cells that were cocultured with shMir126a-expressing ECs or cultured alone. The highest miR-126 levels were found in the LT-HSCs that were attached to control ECs (Fig. 4h) . Next, we transplanted CML LT-HSCs (CD45.2; 1,000 cells/mouse) that had been cocultured for 96 h with shControl-or shMir126a-expressing ECs, or cultured alone, into congenic CD45.1 recipient mice. Mice transplanted with CML LT-HSCs that were cocultured with shControl-expressing ECs had higher white blood cell (WBC) counts, higher CML engraftment levels and reduced survival (P = 0.04), as compared to mice transplanted with CML LT-HSCs that had been either cocultured with shMir126aexpressing ECs or cultured alone ( Fig. 4i-k) .
A recent report showed that in normal BM, Sca-1 + ECs from arterial blood vessels are associated with quiescent HSCs, whereas Sca-1 − ECs from permeable sinusoidal blood vessels are associated with proliferative HSCs 10 . We hypothesized that a similar association between EC immunophenotypic subpopulations and the cell cycle status of adjacent LT-HSCs may exist in CML mice and, given the role of miR-126 in cell quiescence, correlate with miR-126 levels. After sorting ECs and LT-HSCs from the endosteal and central marrow of CML and normal mice, we found that >70% of endosteal ECs were Sca-1 + and >80% of central marrow ECs were Sca-1 − ; furthermore, Sca-1 + ECs expressed higher levels of miR-126 than did Sca-1 − ECs, and total endosteal ECs had higher levels of miR-126 than did total central marrow ECs (Fig. 4l-o) . Accordingly, endosteal LT-HSCs had higher levels of miR-126 ( Fig. 4p ) and were more quiescent ( Fig. 4q-s ) than central marrow LT-HSCs. These results demonstrate a direct association between miR-126 levels in ECs and the cell cycle status of adjacent LT-HSCs and support the concept that there is active trafficking of miR-126 from ECs to LT-HSCs in vivo.
To test the functional role of EC-supplied miR-126 in leukemia cell growth, we generated CML or normal mice carrying loxP-flanked (floxed) Mir126a alleles (Mir126a flox/flox ) to enable conditional knockout (c-KO) of Mir126a expression in LT-HSCs, ECs or both. To generate these mice, we crossed Mir126a flox/flox mice with Mx1-Cre (in which the Cre recombinase is expressed in hematopoietic cells) or Tie2-Cre (in which Cre is expressed in ECs) mice, followed by crossing with SCLtTA×BCR-ABL transgenic mice. These crosses led to the generation of the following strains: Mir126a flox/flox ;Mx1-Cre mice, SCLtTA×BCR-ABL;Mir126a flox/flox ;Mx1-Cre mice, Mir126a flox/WT ; Tie2-Cre mice and Mir126a flox/flox ;Tie2-Cre mice. After injecting Mir126a flox/flox ;Mx1-Cre (hereafter referred to as Mx1 + ) mice with polyinosine-polycytosine (pIpC) to delete Mir126a in normal HSCs, we observed no significant changes in WBC counts in PB (data not shown) or BM mononuclear cell subpopulations (including LT-HSCs) ( Fig. 5a,b ) after 16 weeks of follow-up, as compared to control (Mir126a flox/flox (no expression of Mx1-Cre); hereafter referred to as Mx1 − ) mice. Using SCLtTA×BCR-ABL Mx1 + mice, we were able to target Mir126a deletion in CML LSCs by withdrawing tetracycline to induce BCR-ABL expression and injecting pIpC to induce Cre expression. In these mice, miR-126 levels in BM cells were reduced by 60%, CML development was delayed (P = 0.047), and survival was increased (P = 0.04), as compared to similarly treated SCLtTA×BCR-ABL Mxl − control mice ( Fig. 5c-e ). To confirm that these results are not attributable to 'leaky' miR-126 downregulation in the nonhematopoietic compartment, we sorted CD45.2 CML LT-HSCs from BCR-ABL-induced and pIpC-injected SCLtTA×BCR-ABL Mx1 + or Mx1 − mice and transplanted these cells into CD45.1 congenic recipient mice ( Fig. 5f ). Recipients transplanted with Mx1 + (Mir126a-KO) CML LT-HSCs showed a trend for decreased CML development and increased survival, as compared to recipient mice transplanted with Mx1 − control CML LT-HSCs ( Fig. 5g-j) .
To assess the contribution of EC-derived miR-126 in leukemia, we sorted LT-HSCs from BCR-ABL-induced CD45.1/CD45.2 SCLtTA×BCR-ABL mice (used to track donor cells, and generated by crossing CD45.2 SCLtTA×BCR-ABL B6 mice with CD45.1 B6 mice) (d) Immunoprecipitation (IP) with anti-SPRED1 followed by immunoblotting (IB) with SPRED1-specific and phosphotyrosine (p-Tyr)-specific antibodies (left) and an in vitro kinase assay (right), as performed by IP with anti-c-ABL or anti-mouse-IgG as control and immunoblotting with anti-SPRED1, in lysates of K562 cells that were untreated or treated with DMSO (vehicle) or NIL. (e) IP with anti-RAN followed by IB with anti-SPRED1 and anti-RAN in lysates of K562 cells. (f) IF images for SPRED1 and RAN expression in K562 cells that were untreated or treated with DMSO or NIL. Scale bars, 2 µm and 1 µm (merge). (g) SPRED1, RAN, RCC1 and EXP5 expression in cytoplasmic (Cyt) and nuclear (Nu) fractions from K562 cells that were treated with DMSO or NIL, as assessed by IB analysis. Densitometric quantification of selected bands is shown (normalized to the actin loading control for total and Cyt lysates or to the poly (ADP ribose) polymerase (PARP) loading control for Nu lysates). (h) IP with anti-RAN followed by IB with anti-SPRED1, anti-RAN, anti-EXP5 and anti-RCC1 in lysates of K562 cells, CML CD34 + cells and normal CD34 + cells treated with DMSO or NIL. Densitometric quantification of selected bands is shown (normalized to the actin loading control). (i) Mature miR-126, pri-miR-126 and pre-miR-126 expression, as assessed by qPCR, in K562 and CML CD34 + cells that were treated with DMSO or NIL (n = 3 independent experiments per cell type). (j) IP with anti-RAN followed by IB with anti-SPRED1, anti-EXP5, anti-RCC1 or anti-RAN in lysates of K562 cells without or with washing-off of NIL. Densitometric quantification of selected bands is shown (normalized to the actin loading control). (k-m) Mature miR-126 and pri-miR-126 expression, as assessed by qPCR (n = 3 independent experiments) (k) and miR-126 staining (l), and mature miR-126 and pre-miR-126 levels, as assessed by northern blotting (m), in K562 cells with or without washing-off of NIL. Scale bar, 5 µm. (n) IP with anti-RAN followed by IB with anti-EXP5, anti-RCC1 and anti-RAN in lysates of K562 and CML CD34 + cells without (scrambled control; siSCR) or with knockdown of SPRED1 (siSPRED1) expression. Densitometric quantification of selected bands is shown (normalized to the actin loading control). (o,p) Mature miR-126, pri-miR-126 and pre-miR-126 expression, as assessed by qPCR (n = 3 independent experiments) (o) and miR-126 staining (p), in siSCR-and siSPRED1-treated K562 cells. Scale bar, 5 µm. (q-s) Mature miR-126, pri-miR-126 and pre-miR-126 expression, as assessed by qPCR (n = 3 independent experiments) (q) and miR-126 staining (r), in K562 cells without (siSCR) or with RAN KD (siRAN), as assessed by IB analysis with anti-RNA and anti-actin (s). The IF, IP, IB and miRNA staining experiments in c-h,j,l-n,p,r,s were repeated at least twice using independent samples, with similar results. Full-length gels and blots, with molecular-weight standards, for d,e,g,h,j,m,n,q are provided in Supplementary Figures 8-10 . Throughout, results shown represent mean ± s.e.m. *P ≤ 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; by two-tailed, unpaired Student's t-test. and transplanted these cells into CD45.2 congenic Mir126a flox/flox ; Tie2-Cre − (hereafter referred to as 'Tie2 − ' mice; homozygous expression of Mir126a in ECs), Mir126a flox/WT ;Tie2-Cre + (hereafter referred to as 'het Tie2 + ' mice; heterozygous expression of Mir126a in ECs), or Mir126a flox/flox ;Tie2-Cre + (hereafter referred to as 'hom Tie2 + ' mice; no expression of Mir126a in ECs) recipient mice ( Fig. 5k) . Both het and hom Tie2 + recipient mice showed reduced CML cell engraftment, delayed CML development and significantly increased survival, as compared to Tie2 − recipients at 16 weeks after transplantation (P = 0.009 and P = 0.0003 for survival of het Tie2 + and hom Tie2 + mice, respectively; Fig. 5l-o) . A miR-126 dosage effect was evident, as 70% of hom Tie2 + mice versus 10% of het Tie2 + mice were alive at 28 weeks after transplantation ( Fig. 5o) . Of note, no significant differences in donor cell output from transplanted normal Normal CML ** * * * P = 0.07 0.0025 0.0020 0.0015 0.0010 0.0005 0.0000 LT-HSCs (CD45.1) were observed in the PB and BM from CD45.2 het Tie2 + recipients relative to that from het Tie2 − recipients after 16 weeks of follow-up (data not shown).
Next, to assess the functional effect of concurrent Mir126a KO in both LT-HSCs and ECs, CML LT-HSCs from BCR-ABL-induced and pIpC-injected SCLtTA×BCR-ABL Mx1 + or Mx1 − mice were transplanted into het Tie2 + or het Tie2 − recipient mice, respectively ( Fig. 5p) . Het Tie2 + mice transplanted with Mx1 + CML LT-HSCs showed significantly delayed CML development (P = 0.007) and prolonged survival (P = 0.002) as compared with het Tie2 − mice transplanted with Mx1 − CML LT-HSCs (Fig. 5q,r LT-HSCs, but none of the controls with intact Mir126a in both ECs and LT-HSCs, were alive. Taken together, these results support a functional role of EC-derived miR-126 in sustaining leukemia in the CML LSC niche.
In assessing the relevance of these results to humans, we first showed that human umbilical vein ECs (HUVECs) expressed significantly higher levels of miR-126 than human CML CD34 + subpopulations (P < 0.0001; Supplementary Fig. 2a ). We next transduced the HUVECs with a lentiviral vector encoding shMIR126 (to knock down MIR126 expression) or shControl (Supplementary Fig. 2b,c) and then cocultured CML Lin − CD34 + CD38 − cells (HSCs) with the shMIR126expressing or control HUVECs for 96 h. CML HSCs cocultured for 96 h with control HUVECs had significantly higher miR-126 expression (P < 0.01; Supplementary Fig. 2d,e ), decreased cell cycle entry and apoptosis ( Supplementary Fig. 2f-h) , and a greater proportion of CD34 + cells (Supplementary Fig. 2i ) than CML cells cocultured with shMIR126-expressing HUVECs or cultured alone. Next, we transplanted CML CD34 + cells that had been cocultured with control or shMIR126-expressing HUVECs, or cultured alone, for 96 h into irradiated (300 cGy) immunodeficient NSG-SGM3 mice. At 16 weeks after transplantation, BCR-ABL expression in BM cells confirmed CML cell engraftment in the recipient mice (Supplementary Fig. 2j) . Human CD45 + cell engraftment was substantially increased in the mice that received CML cells cocultured with control HUVECs as compared to the mice that received CML cells cocultured with shMIR126-expressing HUVECs or cultured alone (Supplementary Fig. 2k,l) .
Extracellular vesicles mediate miR-126 trafficking from ECs to LT-HSCs
To test whether intercellular miR-126 trafficking between ECs and HSCs involves extracellular vesicles (EVs), we isolated EVs from control and shMIR126-expressing HUVECs by differential ultracentrifugation. Using electron microscopy and nanoparticle tracking analysis by NanoSight, we found that the size range of the EVs isolated from the supernatants of both control and shMIR126-expressing HUVECs was 40 to 150 nm (peaks at 105 and 125 nm, respectively; Supplementary Fig. 3a,b) . By western blotting analysis, EVs recovered from HUVECs showed expression of exosome-specific proteins (CD63 and TSG101) and an EV-associated protein (HSP90) 21, 22 and lack of a non-EV-associated protein (the mitochondrial protein cytochrome c) ( Supplementary Fig. 3c ). Next, we fractionated EVs from HUVECs using magnetic beads coated with a CD63-specific antibody and confirmed expression of exosome-specific proteins in the CD63 + EV fraction by using antibodies to tetraspanins (CD63, CD9 and CD81) by cytofluorimetric analysis (Supplementary  Fig. 3d ). Significantly higher miR-126 levels were found in the CD63 + EV fraction as compared to the CD63 − EV fraction, as assessed by qPCR (0.77 versus 0.19; P = 0.0007; Supplementary  Fig. 3e) . Notably, miR-126 levels were higher in EVs obtained from control HUVECs than in EVs from shMIR126-expressing HUVECs or EVs from normal or CML human Lin − CD34 + CD38 − HSC cells (Supplementary Fig. 3f ).
To demonstrate intercellular trafficking of miR-126, we labeled miR-126 with a fluorescent probe in cultured HUVECs (Supplementary Fig. 3g ) and subjected the supernatant from these cells to differential ultracentrifugation to collect EVs; treatment of BCR-ABL + K562 cells with the collected HUVEC EVs resulted in the presence of the miR-126 fluorescence signal in the K562 cells, as assessed by confocal microscopy (Supplementary Fig. 3h ). To corroborate these results, we cultured human CML HSCs for 96 h either alone or with EVs (5 × 10 9 particles/ml as measured by NanoSight, equivalent to 5 µg/ml as measured by standard protein quantification methodology) that were isolated from control or shMIR126-expressing HUVECs. CML HSCs cocultured with control-HUVEC-derived EVs had significantly increased miR-126 levels (P < 0.01; Supplementary Fig. 3i ) and reduced cell cycling and apoptosis rates (Supplementary Fig. 3j-m) as compared to CML HSCs cocultured with EVs derived from shMIR126-expressing HUVECs or cultured alone. Next, we either cocultured Mir126a-KO CML LT-HSCs from tetracycline-off and pIpC-injected SCLtTA×BCR-ABL Mx1 + mice with EVs derived from control or shMIR126-expressing HUVECs for 48 h or cultured the Mir126a-KO CML LT-HSCs alone. Mir126a-KO CML cells that were cocultured with control-HUVECderived EVs showed significantly increased miR-126 levels (P < 0.05; Supplementary Fig. 3n ) and reduced cell cycling and apoptosis rates (data not shown) as compared with Mir126a-KO CML cells that were either cocultured with EVs derived from shMIR126-expressing HUVECs or cultured alone.
Next we transplanted primary CML CD34 + cells that were cocultured with EVs (5 × 10 9 particles/ml) from control or shMIR126expressing HUVECs for 96 h into NSG-SGM3 mice. Mice that received cells cocultured with control-HUVEC-derived EVs showed enhanced human CD45 + (P = 0.001; Supplementary Fig. 3o ) and CD45 + CD34 + (P = 0.0008; Supplementary Fig. 3p ) BM engraftment after 16 weeks, as compared mice that received cells that were cocultured with EVs derived from shMIR126-expressing HUVECs. qPCR analysis confirmed that the engrafted cells in both groups of mice were BCR-ABL + (data not shown). We also sorted CML LT-HSCs from induced CD45.2 SCLtTA×BCR-ABL mice and cocultured them with EVs derived from control or shMIR126-expressing HUVECs for 96 h and then transplanted the cells into CD45.1 recipient mice. LT-HSCs that were cocultured with control-HUVEC-derived EVs showed increased miR-126 expression (P = 0.009; Supplementary Fig. 3q ), enhanced CML progression (P = 0.002), an increased engraftment rate (P = 0.06) and reduced survival (P = 0.04), as compared to LT-HSCs cocultured with EVs derived from shMIR126-expressing HUVECs (Supplementary Fig. 3r-t) . Taken together, these observations suggested that EV-mediated trafficking was responsible for the transfer of miR-126 from ECs to LT-HSCs.
Although we could not completely exclude the possibility that decreased CML LT-HSC quiescence and engraftment capacity might have resulted from functional changes in ECs induced by Mir126a KD, rather than from a decrease in miR-126 trafficking from ECs to LT-HSCs, Kuo et al. previously showed that Mir126a-KO mice have no substantial changes in BM EC structure 9 . Moreover, we did not observe detectable changes in the morphology and growth rate of shMIR126-expressing HUVECs or Mir126a-KD mouse ECs as compared to controls (data not shown).
Knockdown of miR-126 expression enhances TKI-mediated targeting of CML LSCs
Given that BCR-ABL activity reduces endogenous levels of miR-126 in LT-HSCs and that pharmacologic inhibition of BCR-ABL by NIL treatment increased miR-126 levels and the frequency of quiescent LT-HSCs ( Fig. 2d-o) , we postulated that miR-126 downregulation may enhance the anti-leukemic activity of TKI treatment and eliminate CML LSCs. To test this hypothesis, we subjected human CML HSCs to MIR126 KD or OE by transduction of GFP-expressing lentiviruses (Supplementary Fig. 4a ). We selected GFP + cells and cultured them for 96 h in the presence of NIL. Combined MIR126 KD and NIL treatment resulted in increased cell cycling and apoptosis (Supplementary Fig. 4b,c) and decreased cell growth, CFC and CFC-replating efficiency (Supplementary Fig. 4d-f) , as compared to only NIL-treated control cells. Conversely, combined miR-126 OE and NIL treatment resulted in decreased cell cycling and apoptosis and increased CFC and CFC-replating efficiency ( Supplementary  Fig. 4b,c ,e,f) relative to only NIL-treated control cells. We obtained similar results for CML LT-HSCs from SCLtTA×BCR-ABL mice (Supplementary Fig. 4g-k) .
To further test the concept that knockdown of miR-126 expression can enhance the anti-leukemic activity of TKI treatment, we transduced human CML HSCs with lentiviral vectors encoding shMIR126 or shControl; we selected GFP + cells and treated them with NIL for 96 h and then transplanted them into irradiated NSG-SGM3 mice. Recipient mice that received NIL-treated shMIR126-expressing cells showed reduced engraftment of human CD45 + cells in PB at 4 weeks after transplantation ( Fig. 6a) and in BM at 16 weeks after transplantation ( Fig. 6b and Supplementary Fig. 5a) , as compared to the controls. BCR-ABL1 levels were reduced in BM cells from NSG-SGM3 mice that were transplanted with shMIR126-expressing CML cells as compared to mice that were transplanted with control CML cells (Supplementary Fig. 5b) .
To test whether miR-126 downregulation in ECs also enhanced the sensitivity of CML HSCs to TKI treatment, we cultured human CML HSCs alone or with HUVECs in which MIR126 expression was knocked down or not, and with or without NIL treatment, for 72 h. CML HSCs cocultured with shMIR126-expressing HUVECs had significantly increased apoptosis and decreased cell growth and CFCs, as compared to CML HSCs cocultured with control HUVECs with or without NIL treatment (Supplementary Fig. 5c-e ). Of note, CML HSCs cocultured with EVs derived from shMIR126-expressing HUVECs also showed increased apoptosis and decreased cell growth as compared to CML HSCs cocultured with control-HUVEC-derived EVs, with or without NIL treatment (Supplementary Fig. 5f,g) . Next we sorted CML LT-HSCs from induced CD45.1/CD45.2 SCLtTA×BCR-ABL mice and transplanted them into CD45.2 het Tie2 + (heterozygous Mir126a-KO allele in ECs) or Tie2 − (WT Mir126a allele in ECs) mice. After confirming CML development, we treated the mice with NIL (50 mg per kg body weight (mg/kg), daily by oral gavage) or vehicle for 3 weeks. Vehicle-treated het Tie2 + mice showed delayed CML development (P = 0.02) and increased survival (P = 0.001) as compared to vehicle-treated Tie2 − mice ( Fig. 6c-e) . Moreover, NIL-treated het Tie2 + mice showed significantly reduced WBC counts in PB (P = 0.03) and increased survival (P = 0.02) as compared to NIL-treated het Tie2 − mice ( Fig. 6c-e) , and all of the NIL-treated het Tie2 + mice were alive at day 150 after transplantation (Fig. 6e) . Taken together, these results support the hypothesis that miR-126 downregulation in ECs and CML HSCs enhances the anti-leukemic activity of TKI treatment. , and numbers of donor CML LT-HSCs in spleen (n) and BM (o) of recipient mice that were transplanted with CML BM cells and then treated with scrRNA (n = 9 mice), inhibitor (n = 7 mice), scrRNA + NIL (n = 8 mice) or inhibitor + NIL (n = 10 mice) for 3 weeks. (p) Survival of another cohort of CML mice that were treated with scrRNA (n = 9 mice), inhibitor (n = 8 mice), scrRNA + NIL (n = 8 mice) or inhibitor + NIL (n = 9 mice) for 3 weeks. (q) Frequency of leukemia-initiating cells (LICs) in BM cells from treated mice with leukemia, as assessed by leukemia development rate in secondary recipient mice that were transplanted with 4 × 10 6 , 2 × 10 6 , 1 × 10 6 or 5 × 10 5 BM cells/mouse from the treated mice (n = 6 mice/dose/condition × 4 doses × 4 conditions = 96 mice) by L-Calc software. Throughout, results shown represent mean ± s.e.m. *P ≤ 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n.s., not significant; by two-tailed, unpaired Student's t-test (a-d,f-o) or log-rank test (e,p).
To sort out the mechanistic basis by which knock down of miR-126 expression enhances TKI activity, we showed that, consistent with previous studies 23, 24 , NIL treatment enhanced activation of the MAPK-ERK signaling pathway and increased expression of the apoptosis regulator BCL-2, thereby promoting survival in CML CD34 + cells (Supplementary Fig. 5h) . Thus, we reasoned that NIL treatment might enhance MAPK-ERK activation through upregulation of miR-126 and consequent downregulation of SPRED1 ( Supplementary  Fig. 5h,i) , a reported inhibitor of the MAPK-ERK pathway. Indeed, knockdown of miR-126 expression in CML CD34 + cells resulted in SPRED1 upregulation and decreased phospho-ERK (p-ERK) and BCL-2 levels (Supplementary Fig. 5j,k) , whereas SPRED1 KD increased p-ERK and BCL-2 levels and rescued NIL-induced apoptosis ( Supplementary Fig. 5l-o) . Moreover, NIL-induced apoptosis was enhanced by treatment with the MAPK pathway inhibitor PD0325901 or by BCL2 KD (Supplementary Fig. 5p-s) . These results support a model in which NIL-induced upregulation of miR-126 expression decreases SPRED1 expression, which results in spurious activation of the MAPK-ERK pathway and ultimately in an increase in BCL-2 levels. Knockdown of miR-126 expression counteracted these effects, thereby increasing the anti-leukemic activity of NIL.
Effective in vitro and in vivo uptake and gene silencing effects of the CpG-miR-126 inhibitor In view of the enhancing effects of miR-126 KD on the anti-leukemic activity of NIL, we reasoned that miR-126 could represent a therapeutic target for eliminating LSC. Although miRNAs can be targeted with oligonucleotide therapeutics (ONTs), it remains challenging to achieve efficient and cell-selective delivery of ONTs in vivo. Thus, we designed a novel miR-126 inhibitor by linking a Mir126aspecific antisense oligodeoxynucleotide (ODN) to a cytosine-guanine dinucleotide (CpG) ODN, a ligand for the intracellular protein Toll-like receptor 9 (TLR9). To allow for systemic administration, we chemically modified the CpG-miR-126 inhibitor (CpG-miR-126i) to resist serum nucleases by using phosphothioation and 2′ O-methylmodified nucleotides in the CpG ODN and anti-miR-126 moieties, respectively. We compared the specificity and efficiency of CpG-miR-126i uptake with a nanoparticle (NP) delivery method previously reported by our group 6 . We incubated K562 cells with fluorescently labeled CpG-miR-126i-Cy3 (CpG), human CD45-specific antibody (Ab)-or transferrin (TF)-conjugated NPs containing miR-126i-Cy3 (Ab-NP or TF-NP), or naked miR-126i-Cy3 (control), in the absence of any reagents routinely used for nucleic acid transfection. Flow cytometric analysis at 4 h and 24 h after treatment ( Supplementary  Fig. 6a,b) showed that CpG-miR-126i-Cy3 was taken up by 99% of the K562 cells at both 4 h and 24 h, as compared to 24% and 30% of the cells incubated with Ab-NP and 74% and 88% of the cells incubated with TF-NP at 4 h and 24 h, respectively. K562 cells did not take up naked miR-126i (control) (Supplementary Fig. 6b) . Efficient miR-126 downregulation by CpG-miR-126i-Cy3 in K562 cells was shown at 24 h (Supplementary Fig. 6c ). We further showed by flow cytometry that, even without routinely used transfection reagents, the CpG-miR-126i-Cy3 was internalized by HUVECs, as well as by human normal and CML Lin − CD34 + CD38 − cells at 4 h ( Supplementary  Fig. 6d-f) ; >95% cells were positive for CpG-miR-126i-Cy3 uptake in all three cell types. CpG-miR-126i-Cy3 uptake led to efficient miR-126 downregulation in HUVECs and HSCs (Supplementary Fig. 6g-i) .
We also observed increased cell cycling in both CpG-miR-126i-treated normal and CML HSCs, as compared to CpG-scrambled RNA (scrRNA)-treated controls (Supplementary Fig. 6j,k) .
Next we evaluated CpG-miR-126i-Cy3 uptake in mouse LT-HSCs and ECs in vitro and in vivo. Following in vitro exposure to CpG-miR-126i-Cy3, efficient uptake at 4 h and Mir126a downregulation at 24 h were shown by flow cytometry and qPCR, respectively ( Supplementary Fig. 6l,m) . We also observed increased cell cycling in normal and CML BM LT-HSCs that were treated with CpG-miR-126i (Supplementary Fig. 6n ). We treated normal and CML mice with one dose (5 mg/kg, by intravenous (i.v.) injection) of CpG-miR-126i-Cy3. At 16 h after treatment, efficient in vivo uptake was demonstrated by flow cytometry in both LT-HSCs (56 ± 5%) and ECs (62 ± 3%) isolated from femurs (Supplementary Fig. 6o) . After CpG-miR-126i treatment (5 mg/kg/d, i.v., daily) for 3 d, we sorted LT-HSCs and ECs and found substantial downregulation of miR-126 expression ( Supplementary Fig. 6p,q) .
CpG-miR-126i enhances in vivo targeting of CML LSCs in combination with TKI treatment
We next tested the effects of CpG-miR-126i in healthy mice to ensure that the compound did not have hematologic toxicity. We treated WT B6 mice with CpG-scrRNA or CpG-miR-126i (inhibitor; 5 mg/kg/d, i.v.) for 3 weeks, after which we collected their BM cells and transplanted them into recipient mice (3 × 10 5 BM cells/mouse). As compared with CpG-scrRNA-treated control mice, inhibitor-treated mice showed increased numbers of red blood cells (RBCs) but no significant differences in the numbers of WBCs or platelets (PLTs) in the PB (Supplementary Fig. 7a-c) or in the numbers of mononuclear cells, LT-HSCs or ECs in the BM (Supplementary Fig. 7d-f) . These findings are consistent with the observation that miR-126 downregulation in normal HSCs increases hematological output 4 . In the recipient mice that received BM cells from donor mice treated with CpG-scrRNA or inhibitor, we observed no significant differences in donor cell engraftment in the PB, BM or spleen (Supplementary Fig. 7g,h) , or in donor LT-HSC numbers in the BM (Supplementary Fig. 7i) , at 16 weeks after transplantation. These data demonstrated that the inhibitor lacked preclinical toxicity for normal hematopoiesis.
We then tested the effects of the inhibitor alone or in combination with NIL on human and mouse CML LT-HSCs in vivo. First, we transplanted human CD34 + cells from patients with chronic-phase CML into NSG-SGM3 mice. At 6 weeks after transplantation, the mice were divided into four groups and treated with CpG-scrRNA (5 mg/kg, i.v., four times a week), inhibitor (5 mg/kg, i.v., four times a week), CpG-scrRNA + NIL (50 mg/kg, daily by oral gavage) or inhibitor + NIL for 3 weeks, followed by assessment of human cell engraftment in PB, BM and spleen. We observed significantly reduced human CD45 + cell, CD45 + CD34 + CD38 − HSC and CD45 + CD34 + CD38 − CD90 + LT-HSC engraftment in the BM of mice that were treated with inhibitor + NIL, as compared to mice that were treated with CpG-scrRNA alone, inhibitor alone or scrRNA + NIL (Fig. 6f-h and Supplementary Fig. 7j) . qPCR analyses confirmed that the engrafted human CD45 + cells were BCR-ABL1 positive (Supplementary Fig. 7k ).
Next we transplanted BM cells from SCLtTA×BCR-ABL mice (CD45.2) into congenic B6 mice (CD45.1). Following confirmation of CML development at 4 weeks after transplantation, mice were treated as described above with CpG-scrRNA, inhibitor, CpG-scrRNA + NIL or inhibitor + NIL for 3 weeks. Because EC-derived miR-126 has a key role in LSC maintenance, we sorted BM ECs from treated mice and confirmed that there were significantly lower miR-126 levels in total ECs, Sca-1 + ECs and Sca-1 − ECs from inhibitor-treated mice, as compared to CpG-scrRNA-treated mice (Supplementary Fig. 7l,m) . Mice that received the combination of inhibitor + NIL had a significant reduction in the percentage of CD45.2 + CML cells in the PB, spleen and BM (Fig. 6i-k) , and a significant reduction in the numbers of CML LSK cells and LT-HSCs in the spleen and BM, as compared to all of the other groups ( Fig. 6l-o) . We followed a cohort of mice for survival studies after 3 weeks of treatment and found that all of the mice that were treated with CpG-scrRNA alone died of leukemia within 60 d after the discontinuation of treatment, whereas 50% of the mice that were treated with inhibitor alone or with scrRNA + NIL, and 90% of the mice that were treated with the combination of inhibitor + NIL, survived (P = 0.0012; Fig. 6p) .
To quantify the frequency of leukemia-initiating cells (LICs) after treatment, BM cells from mice with leukemia that were treated with CpG-scrRNA, inhibitor, CpG-scrRNA + NIL or inhibitor + NIL for 3 weeks were transplanted in limiting dilution assays into secondary congenic CD45.1 recipient mice. Treatment with the combination of inhibitor + NIL resulted in a significantly higher level of depletion of LICs, as assessed by leukemia development in secondary recipient mice after 16 weeks of follow up, as compared to mice that were treated with CpG-scrRNA alone, inhibitor alone or CpG-scrRNA + NIL (Fig. 6q) . None of the secondary recipients that received BM cells from the mice treated with the combination of inhibitor + NIL developed leukemia. These results indicated that, as compared with NIL treatment only, treatment with a combination of NIL and the CpG-miR-126i enhanced the eradication of CML LSCs that were capable of engraftment in secondary recipients.
DISCUSSION
We report here that miR-126 expression levels in both human and mouse CML cells follow the hierarchy of hematopoietic differentiation, with more primitive hematopoietic stem cells or progenitors expressing higher levels of miR-126 than mature cells. Moreover, quiescent CML LT-HSCs had higher levels of miR-126 and a higher leukemia engraftment capacity than proliferating CML LT-HSCs, consistent with findings reported for normal hematopoiesis 4 . Unexpectedly, we found that miR-126 levels were significantly lower in CML LT-HSCs than in their normal counterparts, consistent with previous findings showing that a lower frequency of long-term repopulating cells are observed within CML LT-HSCs as compared to normal LT-HSCs 2 . Indeed, we demonstrated that BCR-ABL expression lowered mature miR-126 levels and increased pri-and pre-miR-126 levels, whereas pharmacological inhibition of BCR-ABL activity by a TKI increased mature miR-126 levels and decreased pri-and pre-miR-126 levels. Taken together, these data support a role for BCR-ABL in altering the biogenesis of endogenous miR-126.
To our knowledge, BCR-ABL-dependent downregulation of miR-126 in CML cells has not been previously reported. SPRED1, a validated miR-126 target 4, 7, 9, 13, 14 , is a tyrosine kinase substrate known to inhibit growth-factor-mediated activation of RAS protein family members and, in turn, the RAS-MAPK-ERK pathway 15 . Tyrosine residue phosphorylation is required for SPRED1 inhibition of RAS-MAPK-ERK activation 16 . We show here that SPRED1 is a substrate for BCR-ABL and that BCR-ABL-induced SPRED1 phosphorylation is critical for miR-126 biogenesis in CML. We found that BCR-ABL-phosphorylated SPRED1 binds with RAN, a RAS family member, disrupts the RAN-EXP5-RCC1 complex, which is involved in pre-miRNA nucleus-to-cytoplasm shuttling, increases nuclear levels of pri-and pre-miR-126 and decreases cytoplasmic levels of mature miR-126. Conversely, BCR-ABL inhibition disrupted the binding of SPRED1 with RAN, enhanced formation of the RAN-EXP5-RCC1 complex, increased mature miR-126 levels and decreased pri-and pre-miR-126 levels (Supplementary Fig. 1j) .
Because miR-126 is necessary for normal and clonal HSC quiescence and continuous downregulation of miR-126 can cause clonal exhaustion 4, 8 , we reasoned that this autoregulatory loop must be circumvented to maintain a reservoir of quiescent CML LSCs. Previous reports have suggested that BM ECs participate in the regulation of normal hematopoiesis 10, 25 . Here we showed that among cell populations in the leukemic BM niche, ECs expressed the highest miR-126 levels and supplied miR-126 to CML cells, likely through EV trafficking. Furthermore, consistent with previous reports showing that Sca-1 + ECs are associated with quiescent normal HSCs and that Sca-1 − ECs are associated with proliferating normal HSC in the marrow 10 , we found that endosteal Sca-1 + ECs express higher levels of miR-126 than central marrow Sca-1 − ECs and are associated with a larger fraction of quiescent BCR-ABL + LT-HSCs, which also express higher miR-126 levels than proliferating BCR-ABL + LT-HSCs. Our data support a functional interplay between ECs and HSCs in CML, which results in a nonrandom BM distribution of the quiescent CML LSC fraction that is more likely to be found proximal to the high-level miR-126-expressing ECs from the endosteal marrow than to the low-level miR-126-expressing ECs from the central marrow. The functional relevance of the exchange of miR-126 between ECs and LT-HSCs to leukemia growth was demonstrated by showing a decreased engraftment of CML LSCs and improved survival in recipient mice with a Mir126a KO in the endothelial compartment that were transplanted with BCR-ABL + LT-HSCs.
Our results may be clinically relevant to patients with CML who are treated with a TKI. Persistence of CML LSCs during TKI treatment is an active area of investigation, as these agents are remarkably potent against cycling cells but fail to eliminate quiescent CML LSCs 3, 26 . Using primary human CML cells and mouse models of CML, we showed that the resistance of CML LSCs to TKI treatment is likely mediated by decreased levels of phosphorylated SPRED1 due to BCR-ABL inhibition, leading to increased endogenous miR-126 levels, which pushes LSCs into a relatively treatment-refractory quiescent state. Furthermore, miR-126 upregulation in TKI-treated CML CD34 + cells resulted in decreased SPRED1 levels, activation of the MAPK-ERK pathway and increased cell survival 24, 27 . Accordingly, knockdown of miR-126 expression in CML cells and/or ECs enhanced the anti-leukemic activity of TKI treatment by counteracting the undesired TKI-induced miR-126 upregulation. In vivo, all NIL-treated CML mice with a genetic Mir126a KD in ECs survived, demonstrating the therapeutic potential of targeting miR-126 in CML.
For clinical translation of this concept, we designed a novel CpG-miR-126 ODN inhibitor that could efficiently be taken up by both hematopoietic and nonhematopoietic cells in the BM niche. We have previously shown that the uptake of CpG-ODN conjugated molecules depends on endocytosis by scavenger family dextran-sulfate-sensitive receptors (SRs) 28, 29 , which are expressed on the surface of normal and malignant myeloid cells 30, 31 . Following SR-mediated internalization, CpG-conjugates bind to endosomal TLR9, triggering their cytoplasmic release 28 . SRs and TLR9 are both expressed on hematopoietic cells and ECs [32] [33] [34] [35] , and likely facilitate the efficient intracellular delivery of CpG-miR-126i and its subsequent endosomal release and pharmacologic activity. We found that CpG-miR-126i was efficiently taken up by both LT-HSCs and ECs in vitro and in vivo, downregulated miR-126 expression and reduced LT-HSC quiescence and frequency. Combination treatment with CpG-miR-126i and a TKI in CML mice resulted in increased survival, as compared to survival after treatment with either agent alone; moreover, no leukemia development in secondary recipients transplanted with BM cells from combination-treated mice was observed, suggesting that combination treatment resulted in the elimination of CML LSCs. In support of the possibility of clinical translation of this treatment strategy, we observed no hematological toxicity in normal mice that were treated with CpG-miR-126i.
In summary, we report that BCR-ABL-mediated SPRED1 phosphorylation downregulates miR-126 biogenesis in CML LSCs, such that CML LSC quiescence and leukemogenic capacity rely on trafficking of miR-126 from ECs to LSCs in the BM niche ( Supplementary  Fig. 7n) . Consistent with this model, TKI treatment inhibits BCR-ABL-induced SPRED1 phosphorylation, leading to the undesired increase in miR-126 levels. On the basis of the proof-of-concept findings reported here, showing that in vivo treatment of CML mice with a newly developed CpG-miR-126 inhibitor enhances TKI activity in vivo and results in LSC elimination, this CpG-miR-126 inhibitor is now being translated to the clinic for the treatment of patients with CML.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
Human samples. PB and BM samples from healthy individuals ('normal') were obtained from donors at the City of Hope National Medical Center (COHNMC). CP CML samples were obtained from patients who had not received prior TKI treatment from the COHNMC, from the Glasgow Experimental Cancer Medicine Centre and from UK SPIRIT2 clinical trial patient samples (http://spirit-cml.org). All CML samples used in this study are P210 BCR-ABL positive, as confirmed by FISH analysis and qPCR. Mononuclear cells were isolated using Ficoll separation. CD34 + cells were then isolated using a positive magnetic bead selection protocol (Miltenyi Biotec, Germany). All of the patients with CML and the healthy donors signed an informed consent form. Sample acquisition was approved by the Institutional Review Boards at the COHNMC and the Greater Glasgow and Clyde NHS Trust, in accordance with an assurance filed with and approved by the Department of Health and Human Services, and met all requirements of the Declaration of Helsinki.
Mouse studies. Inducible transgenic SCLtTA×BCR-ABL mice in the FVB/N background 2, 12 were backcrossed to the B6 background (CD45.2) for ten generations. Transgenic BCR-ABL mice were maintained on tetracycline-containing water at 0.5 g/liter. Withdrawal of tetracycline results in expression of BCR-ABL and generation of a CML-like disease in these mice 2, 12 . Unless otherwise indicated, BCR-ABL expression was induced for 2-3 weeks by tetracycline withdrawal in 6-to 8-week-old male and female mice, and then BM cells (from both tibias and femurs) were collected for experiments. SCLtTA×BCR-ABL mice (CD45.2, B6) were also bred with CD45.1 B6 mice to produce CD45.1/ CD45.2 SCLtTA×BCR-ABL mice as donors. Mir126a flox/flox mice (B6, from Dr. C.J. Kuo, Stanford University) were crossed with Mx1-Cre, Tie2-Cre (both from The Jackson Laboratory) and SCLtTA×BCR-ABL mice (all B6) to obtain the following strains: Mir126a flox/flox ;Mx1-Cre (referred to as Mx1 + mice), SCLtTA×BCR-ABL;Mir126a flox/flox ;Mx1-Cre (referred to as SCLtTA×BCR-ABL Mx1 + mice), Mir126a flox/WT ;Tie2-Cre (referred to as het Tie2 + mice) and Mir126a flox/flox ;Tie2-Cre (referred to as hom Tie2 − mice). Recipient mice in the CD45.1 B6 background (from Charles River) were used to allow tracking of donor CD45.2 cells after transplantation. Recipients were 6-to 8-week-old male and female mice and were irradiated at 900 cGy within 24 h before transplantation. The number of mice for each study group was chosen based on the expected endpoint variation (i.e., engraftment rate and latency period of leukemia) and on the availability of mice of different strains. Mice of the same gender and age were randomly divided into groups. Investigators were blinded to mouse genotype while performing treatment or monitoring engraftment or survival. Mouse care and experimental procedures were performed in accordance with federal guidelines and protocols and were approved by the Institutional Animal Care and Use Committee at the City of Hope.
Engraftment of human cells in immunodeficient mice. GFP + cells (2 × 10 5 cells/mouse) selected from CML Lin − CD34 + CD38 − cells transduced with miR-Zip anti-miR-126 (miR-126 KD) or control (Ctrl) lentiviruses were cultured with or without NIL (5 µM) for 96 h. Cells were then harvested, washed and transplanted via tail vein injection into sublethally irradiated (300 cGy) 6-to 8-weekold NOD.Cg-Prkdc scid Il2rg tm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ mice (NSG-SGM3, The Jackson Laboratory). Engraftment of human CD45 + cells in PB was monitored at 6 weeks. Mice were euthanized after 16 weeks, and femur marrow contents, spleen cells and blood cells were obtained at necropsy. To assess human cell engraftment, cells were labeled with anti-mouse-CD45, anti-human-CD45 and anti-CD33 antibody and analyzed by flow cytometry. To assess engraftment of malignant BCR-ABL expressing cells, BM cells obtained were evaluated for BCR-ABL1 mRNA levels by qPCR 36 .
In vivo treatment of normal and CML mice. BM cells (CD45.2) were obtained from SCLtTA×BCR-ABL mice at 4 weeks after induction of BCR-ABL expression by tetracycline withdrawal and were then transplanted by tail vein injection (10 6 cells/mouse) into irradiated (900 cGy) recipient mice (CD45.1). Blood samples were obtained 4 weeks after transplantation to confirm development of neutrophilic leukocytosis. Mice were treated with CpG-scrRNA (5 mg/kg, four times a week by tail vein injection), CpG-miR-126i (inhibitor, 5 mg/kg, four times a week by tail vein injection), CpG-scrRNA + NIL (50 mg/kg, daily by oral gavage), or inhibitor + NIL for 21 d. After 3 weeks of treatment, mice were euthanized, and BM cells from the right femur and spleen cells were analyzed for CML cell output. BM cells from the left femur of the treated mice were pooled, and 4 × 10 6 , 2 × 10 6 , 1 × 10 6 and 5 × 10 5 cells/mouse (6 mice/dose × 4 doses × 4 conditions = 96 mice) were transplanted into irradiated (900 cGy) recipient mice (CD45.1). WBC counts and CML cell engraftment were monitored every 4 weeks. The mice were euthanized at 16 weeks, followed by assessment of donor CML cell engraftment in PB, BM and spleen. The fraction of mice showing evidence of CML development at 16 weeks after secondary transplantation was determined, and the frequency of LICs was calculated using L-Calc software. Another cohort of mice was followed for survival up to 60 d after discontinuation of treatment. To determine the in vivo effect of the CpG-miR-126i on normal hematopoiesis, normal mice were treated with CpG-scrRNA or inhibitor for 3 weeks, followed by assessment of WBC, RBC and PLT counts in PB and BM subpopulations in the BM.
Isolation of cells from different marrow regions.
Tibias and femurs were excised from 8-to 12-week-old mice. After removing the muscle and connective tissue, the bones were flushed five times using a 23-gauge needle and 3 ml of cold Iscove's modified Dulbecco's medium (IMDM) and collected as central marrow. The marrow-depleted bones were crushed gently with a mortar and pestle in cold IMDM, and the bone fragments were incubated at 37 °C with 3 ml of 3 mg/ml collagenase I (Sigma) and gently agitated for 45min. The digested bones were then filtered through a 40-µm strainer (BD Biosciences) and collected as endosteal marrow.
Flow cytometry analyses. Human Lin − CD34 + CD38 + committed progenitors, Lin − CD34 + CD38 − and Lin − CD34 + CD38 − CD90 − primitive progenitors, and Lin − CD34 + CD38 − CD90 + stem cells were obtained by flow-cytometrybased sorting. Antibodies to the following human proteins were used: human biotinylated lineage antibodies against CD2 (clone RPA-2.10, cat 555325, BD Biosciences), CD7 (124-1D1, 13-0079-80, eBioscience), CD10 (CB-CALLA, 15259439, ThermoFisher), CD11b (C67F154, 13019682, ThermoFisher), CD19 (eBio1D3 (1D3), 13-0193-82, Thermo Fisher), CD33 (HIM3-4, MA1-19522, Thermo Fisher), CD235a (HIR2 (GA-R2), 13-9987-82, Thermo Fisher); human antibodies against CD34 (PE-Cy7, 581, 560710; FITC, 581, 555821; APC, 581, 555824; all from BD Biosciences), CD38 (PE, HIT2, 560981; APC, HIT2, 555462, both from BD Biosciences), CD90 (PerCP-Cy5.5, eBio5E10 (5E10), 45-0909-42, Thermo Fisher), CD33 (PE, P67.6, 347787, BD Biosciences), CD45 (FITC, 2D1,11-9459-42; PerCP-Cy5.5, 2D1,45-9459-42, Thermo Fisher), CD31 (PE, 390, 50-103-20, Thermo Fisher), K i -67 (PE, B56, 556027; FITC, B56, 556026, BD Biosciences), CD63 (PE-Cy7, H5C6, 561982, BD Biosciences), CD9 (FITC, H19a, 312104, BioLegend), and CD81 (APC, JS81, 561958, BD Biosciences). Mouse cells were obtained from PB, BM (from both tibias and femurs), or spleen. For analysis of stem and progenitor cells, c-kit + cells were selected using antimouse CD117 microbeads or Lin − cells were selected using Lineage depletion microbeads (both from Miltenyi Biotec, San Diego, CA). The following mouse antibodies were used: mouse biotinylated lineage antibodies (all from eBioscience) against: CD3 (clone 17A2, cat 13-0031-85), CD4 (GK1.5, 13-0041-85), CD8 (53-6.7, 13-0083-85), B220 (RA3-6B2, 13-0452-85), CD19 (eBio1D3 (1D3), 13-0193-85), IgM (eB121-15F9, 13-5790-85), Gr-1 (RB6-8C5, 13-5931-85), CD11b (M1/70, 13-0112-85), NK1.1 (PK136, 13-5941-85), Ter119 (clone TER-119, cat 13-5921-85), Flt3 (A2F10, 13-1351-85); mouse antibodies against Flt3 (PE, A2F10, 12-1351-82, eBioscience), Sca-1 (PE-Cy7, D7, 25-5981-82, eBioscience), CD117 (APC-eflu780, ACK2, 47-1172-82, eBioscience), CD16-CD32 (PE-Cy7, 2.4G2, 560829, BD Biosciences), CD34 (Alexa Fluor 647, RAM34, 560230, BD Biosciences), CD150 (PerCP-Cy5.5, TC15-12F12.2, 115922, BioLegend), CD48 (APC, HM48-1,17-0481-82, eBioscience; Pacific blue, HM48-1, 103418, BioLegend), CD45.1(PE-Cy7, A20, 25-0453-82; PerCP-Cy5.5, A20, 45-0453-80, both from eBioscience), CD45.2 (FITC, 104, 11-0454-85; eFluor450, 104,48-0454-82, both from eBioscience), CD45 (PE-Cy7, 30-F11, 25-0451-82, eBioscience), Ter119 (APC-eflu780, TER-119, 50-162-15, eBioscience), CD31 (APC, 390, 17-0311-82; PE, 390, 12-0311-82, both from eBioscience), CD166 (PE, FAB1172P, R&D Systems). Other antibodies include anti-streptavidin (PE, 12-4317-87; FITC, 11-4317-87; PerCP-Cy5.5, 45-4317-80, eBioscience) and
Northern blot analysis. Northern blot analysis was performed using a northern-blot-based protocol (LED) for miRNA detection using digoxigenin (DIG)-labeled miR-126 probes containing locked nucleic acids (LNA) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide for cross-linking the RNA to the membrane. Briefly, total RNA was prepared using Trizol reagent (Life Technologies). 20 µg of total RNA was separated on a 15% TBE-urea gel (Life Technologies) and transferred onto positively charged nylon membranes (Roche). The blots were hybridized with LNA miR-126 probes for 12 h. After washing twice with 2× saline-sodium citrate (SSC) and 0.1× SSC (containing 0.1% SDS), the blots were immunoblotted with an anti-DIG antibody (clone 1.71.256, Roche, 1:1,000 dilution) and exposed.
Small RNA (smRNA) deep-sequencing using Illumina HiSeq2500. LSK cells from non-induced and induced CML mice were sorted, and total RNA was extracted using the miRNeasy Mini Kit (Qiagen, Valencia, CA). smRNA sequencing was performed using Illumina HiSeq2500 at the COH Integrative Genomics Core following the manufacturer's sample-preparation protocol (TruSeq Small RNA Sample Prep kit, Illumina, Inc.) with some modifications. Briefly, 250 ng of total RNA was used for smRNA sequencing-library construction. Total RNA was ligated to the modified 3′ adaptor (5′−TCTGGAATTCTC GGGTGCCAAGGAACTCC) with T4 RNA ligase 2 (truncated; NEB, M0242L) for 1 h at 22 °C. The unligated free 3′ adaptors were blocked by annealing with RT primer (5′-GGAGTTCCTTGGCACCCGAGAATTCCA) at 75 °C for 5 min, 37 °C for 30 min and 25 °C for 15 min. The product subsequently was ligated to the modified 5′ adaptor (5′−GUUCAGAGUUCUACAGUCCGACGAUCNNN) with T4 RNA ligase1 (NEB, M0204L) for 1 h at 20 °C. The constructed smRNA library was reverse-transcribed, then subjected to PCR amplification for 12 cycles using barcoded index primers GX1 (CAAGCAGAA GACGGCATACG AGATNNNNNNGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC) and GX2 (AATGATACGGCGACCACCGAGATCTACACGTTCAGAGTTCTACA GTCCG A) followed by 6% TBE-PAGE gel purification with size selection (for targeted smRNAs of 17-35 nt). The final libraries were sequenced using the Illumina HiSeq2500 platform in the single-read mode of 51 cycles of read1 and seven cycles of index read. Real-time analysis (RTA) 2.2.38 software was used to process the image analysis and base-calling.
Oligonucleotide design and synthesis. The partially phosphothioated ODN and miR-126 inhibitor or scrRNA was linked using 5 U of C3 carbon chain linker, (CH 2 ) 3 (indicated by 'x'). The constructs were also conjugated with Cy3 to track the internalization in cells by flow cytometry. The sequences were as follows:
CpG-miR-126 inhibitor: 5′-G*G*TGCATCGATGCAGG*G*G* G*Gxxxxxm CmGmC mAmUmUmAmUmUmAmCmUmCmAmCmGmGmUmAmCm-GmA -3′; CpG-scrRNA:
5′-G*G*TGCATCGATGCAGG*G*G* G*GxxxxxmGmUmAmGmAmA mCmCmGmUmAmCmUmCmGmUmCmAmCmUmUmA-3′, where the asterisk (*) indicates phosphorothioation. One nonbridging atom of oxygen on phosphate was replaced with sulfur. 'm' indicates the 2′-O-methyl analog of the nucleotide.
Transferrin-or anti-CD45.2-conjugated nanoparticle preparation. Previously we developed a transferrin (TF)-targeted neutral NP delivery system 6, 41 . Briefly, positively charged polyethylenimine and negatively charged miR-126i-Cy3 or scrRNA-Cy3 form a polyplex core. This core was then loaded into pre-made anionic liposomal NPs to form lipopolyplex NPs. The formulation consisted of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dimyristoylsn-glycerol, methoxypolyethylene glycol (DMG-PEG) and linoleic acid. TF or anti-human-CD45 antibody conjugated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPEPEG2000 maleimide) was then post-inserted to the surface of lipopolyplex nanoparticles (to form TF-NP and Ab-NP, respectively). The molar ratio of lipids to TF was 2,000 as previously described 6, 41 , and the molar ratio of lipids to anti-CD45 antibody was optimized to 10,000.
Statistical analysis. Comparison between groups was performed by a twotailed, paired or unpaired Student's t-test. The log-rank test was used to assess significant differences between survival curves. All statistical analyses were performed using Prism version 6.0 software (GraphPad Software). Sample sizes chosen are indicated in the individual figure legends and were not based on formal power calculations to detect prespecified effect sizes. All of the in vitro experiments were performed 3-6 times using biologically independent samples; the in vivo experiments were performed using 6-16 mice in each group. P ≤ 0.05 was considered to be significant. Results shown represent mean ± s.e.m. *P ≤ 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary. Data availability. miRNA deep sequencing data produced in our laboratory and analyzed in this study are available at the Gene Expression Omnibus (GEO) repository of the National Center for Biotechnology Information, under the accession number GSE107431. Supplementary Table 1, Supplementary Figures 1-7 , source data for Figure 3 and Supplementary Figures 3c and 5h ,k,m,p as shown in Supplementary Figures 8-10 , and gating strategy for flow cytometry analysis as shown in Supplementary Figure 11 , are provided with the online version of this paper. All other data sets generated during this study are available from the corresponding author on reasonable request. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity. 
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Data exclusions
Describe any data exclusions. No data were excluded from the analyses.
Replication
Describe whether the experimental findings were reliably reproduced.
All experimental findings were reliably reproduced.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For animal studies, mice with the same gender or age were divided randomly into experimental groups to reduce variation and enhance power.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Investigators were blinded to group allocation during data collection and/or analysis.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section) c. Report whether the cell lines were tested for mycoplasma contamination.
The cell lines were tested negative for mycoplasma contamination.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
The cell lines used are not listed in the database of commonly misidentified cell lines.
